|Day Low/High||8.48 / 8.85|
|52 Wk Low/High||6.64 / 12.83|
Former Attorney General of Louisiana, Charles C. Foti, Jr.
Investors in MiMedx Group Inc saw new options begin trading this week, for the February 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MDXG options chain for the new February 2017 contracts and identified one put and one call contract of particular interest.
Congress puts patients first in passing this groundbreaking legislation
MIMEDX'S PURION PROCESSED dHACM ALLOGRAFTS REPRESENT YEARS OF SCIENTIFIC RIGOR THAT CONFORM TO THE NEW USP-NF MONOGRAPH
In trading on Thursday, shares of MiMedx Group Inc crossed below their 200 day moving average of $8.03, changing hands as low as $7.87 per share. MiMedx Group Inc shares are currently trading down about 5.9% on the day.
MiMedx EpiFix®, AmnioFix®, AmnioFill™ and EpiCord™ Showcased for Wound Healing and Surgical Procedures
$64.4 Million Q3 2016 Revenue is 31% Increase Over Q3 2015
Presentation of Application Techniques and Therapeutic Approaches Using MiMedx EpiFix and AmnioFix for Wound Healing and Surgical Procedures
PRESENTERS OVERWHELMINGLY ASK FDA TO WITHDRAW OR SIGNIFICANTLY MODIFY DRAFT GUIDANCE
Study quantifies in MiMedx dHACM allografts numerous matrix components, growth factors, proteases and protease inhibitors known to play a role in wound healing
AMNIOFILL™ IS THE FIRST PRODUCT IN THE MIMEDX PLACENTAL COLLAGEN MATRIX FAMILY TO BE COMMERCIALLY INTRODUCED
FDA AGREES TO SHORTEN IMMUNOGENIC TESTING BY ONE YEAR IN THE COMPANY'S PLANTAR FASCIITIS STUDY
Trade-Ideas LLC identified MiMedx Group (MDXG) as a weak on high relative volume candidate